niman

nCoV sequences BetaCoV/England/01/2020| (50F) and BetaCoV/England/02/2020| (23M) same lineage as Shenzhen and US (WA, IL, CA, AZ) plus new polymorphisms.

New airports for screening Honolulu Washington-Dulles Newark Dallas Detroit

Causes for concern Number of positives Death outside of China (Philippines) H2H

Seeking approval for (EUA) diagnostics. Sending to state labs in international partners.

Virus isolated

Some of PUI's in transit to CDC

New cases in MA and 4 CA (disclosed over weekend)

Media Advisory For Immediate Release Monday, February 3, 2020 Contact: CDC Media Relations (404) 639-3286 CDC Media Telebriefing: Update on 2019 Novel Coronavirus (2019-nCoV) What The Centers for Disease Control and Prevention (CDC) will provide an update to media on the 2019 Novel Coronavirus response. Who Nancy Messonnier, M.D., Director, National Center for Immunization and Respiratory Diseases When 11:30 a.m. ET Monday, February 3, 2020 Dial-In Media: 800-857-9756 International: 1-212-287-1647 PASSCODE: CDC Media Non-Media: 888-795-0855 International: 1-630-395-0498 PASSCODE: 1792134 Important Instructions Due to anticipated high volume, please plan to dial in to the telebriefing 15 minutes before the start time. Media: If you would like to ask a question during the call, press *1 on your touchtone phone. Press *2 to withdraw your question. You may queue up at any time. You will hear a tone to indicate your question is pending. TRANSCRIPT A transcript will be available following the briefing at CDC’s web site: www.cdc.gov/media. ### U.S. Department of Health and Human Services

CDC Media Telebriefing: Update on 2019 Novel Coronavirus (2019-nCoV) 11:30 a.m. ET Monday, February 3, 2020

Ministry of Health and Family Welfare Update on Novel Coronavirus: third positive case reported in Kerala Posted On: 03 FEB 2020 12:13PM by PIB Delhi Third positive case of Novel Coronavirus patient, has been reported in Kerala. The patient has a travel history from Wuhan in China. The patient has tested positive for Novel Coronavirus and is in isolation in the hospital. The patient is stable and is being closely monitored. **** MV https://pib.gov.in/PressReleseDetail.aspx?PRID=1601681

The 3rd nCoV case has been confirmed in India, and is also Kerala ex-Wutan.

References 1. Richman DD Whitley RJ Hayden FG Clinical virology. 4th edn. ASM Press, Washington2016 View in Article Google Scholar 2. Ksiazek TG Erdman D Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1953-1966 View in Article Google Scholar 3. Kuiken T Fouchier RAM Schutten M et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003; 362: 263-270 View in Article Google Scholar 4. Drosten C Günther S Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1967-1976 View in Article Google Scholar 5. de Groot RJ Baker SC Baric RS et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87: 7790-7792 View in Article Google Scholar 6. Zaki AM van Boheemen S Bestebroer TM Osterhaus ADME Fouchier RAM Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367: 1814-1820 View in Article Google Scholar 7. WHO Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. https://www.who.int/csr/sars/country/table2004_04_21/en/ Date: Dec 31, 2003 Date accessed: January 19, 2020 View in Article Google Scholar 8. WHO Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/ Date: November, 2019 Date accessed: January 19, 2020 View in Article Google Scholar 9. WHO Novel coronavirus – China. http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/ Date: Jan 12, 2020 Date accessed: January 19, 2020 View in Article Google Scholar 10. WHO Novel coronavirus – Thailand (ex-China). http://www.who.int/csr/don/14-january-2020-novel-coronavirus-thailand/en/ Date: Jan 14, 2020 Date accessed: January 19, 2020 View in Article Google Scholar 11. WHO Novel coronavirus – Japan (ex-China). http://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/ Date: Jan 17, 2020 Date accessed: January 19, 2020 View in Article Google Scholar 12. WHO Novel coronavirus – Republic of Korea (ex-China). http://www.who.int/csr/don/21-january-2020-novel-coronavirus-republic-of-korea-ex-china/en/ Date: Jan 21, 2020 Date accessed: January 23, 2020 View in Article Google Scholar 13. CDC First travel-related case of 2019 novel coronavirus detected in United States. https://www.cdc.gov/media/releases/2020/p0121-novel-coronavirus-travel-case.html Date: Jan 21, 2020 Date accessed: January 23, 2020 View in Article Google Scholar 14. Tan W Zhao X Ma X et al. A novel coronavirus genome identified in a cluster of pneumonia cases — Wuhan, China 2019−2020. http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c Date accessed: January 23, 2020 View in Article Google Scholar 15. Sanz F Gimeno C Lloret T et al. Relationship between the presence of hypoxemia and the inflammatory response measured by C-reactive protein in bacteremic pneumococcal pneumonia. Eur Respir J. 2011; 38: 2492 View in Article Google Scholar 16. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group KDIGO clinical practice guideline for acute kidney injury. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf Date: March, 2012 Date accessed: January 23, 2020 View in Article Google Scholar 17. Garner JS Jarvis WR Emori TG Horan TC Hughes JM CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16: 128-140 View in Article Google Scholar 18. Gao C Wang Y Gu X et al. Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. Crit Care Med. 2020; (published online Jan 20) DOI:10.1097/CCM.0000000000004207 View in Article Google Scholar 19. Perlman S Netland J Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009; 7: 439-450 View in Article Google Scholar 20. Lee N Hui D Wu A et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348: 1986-1994 View in Article Google Scholar 21. Assiri A Al-Tawfiq JA Al-Rabeeah AA et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; 13: 752-761 View in Article Google Scholar 22. Wong CK Lam CWK Wu AKL et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136: 95-103 View in Article Google Scholar 23. Mahallawi WH Khabour OF Zhang Q Makhdoum HM Suliman BA MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018; 104: 8-13 View in Article Google Scholar 24. He L Ding Y Zhang Q et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006; 210: 288-297 View in Article Google Scholar 25. Faure E Poissy J Goffard A et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?. PLoS One. 2014; 9e88716 View in Article Google Scholar 26. Falzarano D de Wit E Rasmussen AL et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med. 2013; 19: 1313-1317 View in Article Google Scholar 27. Stockman LJ Bellamy R Garner P SARS: systematic review of treatment effects. PLoS Med. 2006; 3: e343 View in Article Google Scholar 28. Lansbury L Rodrigo C Leonardi-Bee J Nguyen-Van-Tam J Lim WS Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019; 2: CD010406 View in Article Google Scholar 29. Arabi YM Mandourah Y Al-Hameed F et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018; 197: 757-767 View in Article Google Scholar 30. WHO Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected Date: Jan 11, 2020 Date accessed: January 19, 2020 View in Article Google Scholar 31. Chu CM Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252-256 View in Article Google Scholar 32. Arabi YM Alothman A Balkhy HH et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018; 19: 81 View in Article Google Scholar 33. Sheahan TP Sims AC Graham RL et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017; 9eaal3653 View in Article Google Scholar 34. Sheahan TP Sims AC Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11: 222 View in Article Google Scholar 35. Cui J Li F Shi Z-L Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181-192 View in Article Google Scholar 36. Ge X-Y Li J-L Yang X-L et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013; 503: 535-538 View in Article Google Scholar 37. Wang M Hu Z Bats as animal reservoirs for the SARS coronavirus: hypothesis proved after 10 years of virus hunting. Virol Sin. 2013; 28: 315-317 View in Article Google Scholar

Discussion We report here a cohort of 41 patients with laboratory-confirmed 2019-nCoV infection. Patients had serious, sometimes fatal, pneumonia and were admitted to the designated hospital in Wuhan, China, by Jan 2, 2020. Clinical presentations greatly resemble SARS-CoV. Patients with severe illness developed ARDS and required ICU admission and oxygen therapy. The time between hospital admission and ARDS was as short as 2 days. At this stage, the mortality rate is high for 2019-nCoV, because six (15%) of 41 patients in this cohort died. The number of deaths is rising quickly. As of Jan 24, 2020, 835 laboratory-confirmed 2019-nCoV infections were reported in China, with 25 fatal cases. Reports have been released of exported cases in many provinces in China, and in other countries; some health-care workers have also been infected in Wuhan. Taken together, evidence so far indicates human transmission for 2019-nCoV. We are concerned that 2019-nCoV could have acquired the ability for efficient human transmission. 19 Airborne precautions, such as a fit-tested N95 respirator, and other personal protective equipment are strongly recommended. To prevent further spread of the disease in health-care settings that are caring for patients infected with 2019-nCoV, onset of fever and respiratory symptoms should be closely monitored among health-care workers. Testing of respiratory specimens should be done immediately once a diagnosis is suspected. Serum antibodies should be tested among health-care workers before and after their exposure to 2019-nCoV for identification of asymptomatic infections. Similarities of clinical features between 2019-nCoV and previous betacoronavirus infections have been noted. In this cohort, most patients presented with fever, dry cough, dyspnoea, and bilateral ground-glass opacities on chest CT scans. These features of 2019-nCoV infection bear some resemblance to SARS-CoV and MERS-CoV infections. 20 , 21 However, few patients with 2019-nCoV infection had prominent upper respiratory tract signs and symptoms (eg, rhinorrhoea, sneezing, or sore throat), indicating that the target cells might be located in the lower airway. Furthermore, 2019-nCoV patients rarely developed intestinal signs and symptoms (eg, diarrhoea), whereas about 20–25% of patients with MERS-CoV or SARS-CoV infection had diarrhoea. 21 Faecal and urine samples should be tested to exclude a potential alternative route of transmission that is unknown at this stage. The pathophysiology of unusually high pathogenicity for SARS-CoV or MERS-CoV has not been completely understood. Early studies have shown that increased amounts of proinflammatory cytokines in serum (eg, IL1B, IL6, IL12, IFNγ, IP10, and MCP1) were associated with pulmonary inflammation and extensive lung damage in SARS patients. 22 MERS-CoV infection was also reported to induce increased concentrations of proinflammatory cytokines (IFNγ, TNFα, IL15, and IL17). 23 We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFNγ, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNFα than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity. However, 2019-nCoV infection also initiated increased secretion of T-helper-2 (Th2) cytokines (eg, IL4 and IL10) that suppress inflammation, which differs from SARS-CoV infection. 22 Further studies are necessary to characterise the Th1 and Th2 responses in 2019-nCoV infection and to elucidate the pathogenesis. Autopsy or biopsy studies would be the key to understand the disease. In view of the high amount of cytokines induced by SARS-CoV, 22 , 24 MERS-CoV, 25 , 26 and 2019-nCoV infections, corticosteroids were used frequently for treatment of patients with severe illness, for possible benefit by reducing inflammatory-induced lung injury. However, current evidence in patients with SARS and MERS suggests that receiving corticosteroids did not have an effect on mortality, but rather delayed viral clearance. 27 , 28 , 29 Therefore, corticosteroids should not be routinely given systemically, according to WHO interim guidance. 30 Among our cohort of 41 laboratory-confirmed patients with 2019-nCoV infection, corticosteroids were given to very few non-ICU cases, and low-to-moderate dose of corticosteroids were given to less than half of severely ill patients with ARDS. Further evidence is urgently needed to assess whether systematic corticosteroid treatment is beneficial or harmful for patients infected with 2019-nCoV. No antiviral treatment for coronavirus infection has been proven to be effective. In a historical control study, 31 the combination of lopinavir and ritonavir among SARS-CoV patients was associated with substantial clinical benefit (fewer adverse clinical outcomes). Arabi and colleagues initiated a placebo-controlled trial of interferon beta-1b, lopinavir, and ritonavir among patients with MERS infection in Saudi Arabia. 32 Preclinical evidence showed the potent efficacy of remdesivir (a broad-spectrum antiviral nucleotide prodrug) to treat MERS-CoV and SARS-CoV infections. 33 , 34 As 2019-nCoV is an emerging virus, an effective treatment has not been developed for disease resulting from this virus. Since the combination of lopinavir and ritonavir was already available in the designated hospital, a randomised controlled trial has been initiated quickly to assess the efficacy and safety of combined use of lopinavir and ritonavir in patients hospitalised with 2019-nCoV infection. Our study has some limitations. First, for most of the 41 patients, the diagnosis was confirmed with lower respiratory tract specimens and no paired nasopharyngeal swabs were obtained to investigate the difference in the viral RNA detection rate between upper and lower respiratory tract specimens. Serological detection was not done to look for 2019-nCoV antibody rises in 18 patients with undetectable viral RNA. Second, with the limited number of cases, it is difficult to assess host risk factors for disease severity and mortality with multivariable-adjusted methods. This is a modest-sized case series of patients admitted to hospital; collection of standardised data for a larger cohort would help to further define the clinical presentation, natural history, and risk factors. Further studies in outpatient, primary care, or community settings are needed to get a full picture of the spectrum of clinical severity. At the same time, finding of statistical tests and p values should be interpreted with caution, and non-significant p values do not necessarily rule out difference between ICU and non-ICU patients. Third, since the causative pathogen has just been identified, kinetics of viral load and antibody titres were not available. Finally, the potential exposure bias in our study might account for why no paediatric or adolescent patients were reported in this cohort. More effort should be made to answer these questions in future studies. Both SARS-CoV and MERS-CoV were believed to originate in bats, and these infections were transmitted directly to humans from market civets and dromedary camels, respectively. 35 Extensive research on SARS-CoV and MERS-CoV has driven the discovery of many SARS-like and MERS-like coronaviruses in bats. In 2013, Ge and colleagues 36 reported the whole genome sequence of a SARS-like coronavirus in bats with that ability to use human ACE2 as a receptor, thus having replication potentials in human cells. 37 2019-nCoV still needs to be studied deeply in case it becomes a global health threat. Reliable quick pathogen tests and feasible differential diagnosis based on clinical description are crucial for clinicians in their first contact with suspected patients. Because of the pandemic potential of 2019-nCoV, careful surveillance is essential to monitor its future host adaption, viral evolution, infectivity, transmissibility, and pathogenicity. This online publication has been corrected. The corrected version first appeared at thelancet.com on January 30, 2020 Contributors BC and JW had the idea for and designed the study and had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. YWa, GF, XG, JiXu, HL, and BC contributed to writing of the report. BC contributed to critical revision of the report. YWa, GF, XG, JiXu, and HL contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version. Declaration of interests All authors declare no competing interests. Data sharing The data that support the findings of this study are available from the corresponding author on reasonable request. Participant data without names and identifiers will be made available after approval from the corresponding author and National Health Commission. After publication of study findings, the data will be available for others to request. The research team will provide an email address for communication once the data are approved to be shared with others. The proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability to request for our data. The corresponding author and National Health Commission will make a decision based on these materials. Additional materials may also be required during the process. Acknowledgments This work is funded by the Special Project for Emergency of the Ministry of Science and Technology (2020YFC0841300) Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1-003), a National Science Grant for Distinguished Young Scholars (81425001/H0104), the National Key Research and Development Program of China (2018YFC1200102), The Beijing Science and Technology Project (Z19110700660000), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-014), and National Mega-projects for Infectious Diseases in China (2017ZX10103004 and 2018ZX10305409). We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Wuhan; we thank the Chinese National Health Commission for coordinating data collection for patients with 2019-nCoV infection; we thank WHO and the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) for sharing data collection templates publicly on the website; and we thank Prof Chen Wang and Prof George F Gao for guidance in study design and interpretation of results.

Results By Jan 2, 2020, 41 admitted hospital patients were identified as laboratory-confirmed 2019-nCoV infection in Wuhan. 20 [49%]) of the 2019-nCoV-infected patients were aged 25–49 years, and 14 (34%) were aged 50–64 years (figure 1A). The median age of the patients was 49·0 years (IQR 41·0–58·0; table 1). In our cohort of the first 41 patients as of Jan 2, no children or adolescents were infected. Of the 41 patients, 13 (32%) were admitted to the ICU because they required high-flow nasal cannula or higher-level oxygen support measures to correct hypoxaemia. Most of the infected patients were men (30 [73%]); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Figure 1Date of illness onset and age distribution of patients with laboratory-confirmed 2019-nCoV infection Show full caption View Large Image Figure Viewer Download Hi-res image Download (PPT) Table 1Demographics and baseline characteristics of patients infected with 2019-nCoV All patients (n=41) ICU care (n=13) No ICU care (n=28) p value Characteristics Age, years 49·0 (41·0–58·0) 49·0 (41·0–61·0) 49·0 (41·0–57·5) 0·60 Sex .. .. .. 0·24 Men 30 (73%) 11 (85%) 19 (68%) .. Women 11 (27%) 2 (15%) 9 (32%) .. Huanan seafood market exposure 27 (66%) 9 (69%) 18 (64%) 0·75 Current smoking 3 (7%) 0 3 (11%) 0·31 Any comorbidity 13 (32%) 5 (38%) 8 (29%) 0·53 Diabetes 8 (20%) 1 (8%) 7 (25%) 0·16 Hypertension 6 (15%) 2 (15%) 4 (14%) 0·93 Cardiovascular disease 6 (15%) 3 (23%) 3 (11%) 0·32 Chronic obstructive pulmonary disease 1 (2%) 1 (8%) 0 0·14 Malignancy 1 (2%) 0 1 (4%) 0·49 Chronic liver disease 1 (2%) 0 1 (4%) 0·68 Signs and symptoms Fever 40 (98%) 13 (100%) 27 (96%) 0·68 Highest temperature, °C .. .. .. 0·037 <37·3 1 (2%) 0 1 (4%) .. 37·3–38·0 8 (20%) 3 (23%) 5 (18%) .. 38·1–39·0 18 (44%) 7 (54%) 11 (39%) .. >39·0 14 (34%) 3 (23%) 11 (39%) .. Cough 31 (76%) 11 (85%) 20 (71%) 0·35 Myalgia or fatigue 18 (44%) 7 (54%) 11 (39%) 0·38 Sputum production 11/39 (28%) 5 (38%) 6/26 (23%) 0·32 Headache 3/38 (8%) 0 3/25 (12%) 0·10 Haemoptysis 2/39 (5%) 1 (8%) 1/26 (4%) 0·46 Diarrhoea 1/38 (3%) 0 1/25 (4%) 0·66 Dyspnoea 22/40 (55%) 12 (92%) 10/27 (37%) 0·0010 Days from illness onset to dyspnoea 8·0 (5·0–13·0) 8·0 (6·0–17·0) 6·5 (2·0–10·0) 0·22 Days from first admission to transfer 5·0 (1·0–8·0) 8·0 (5·0–14·0) 1·0 (1·0–6·5) 0·0023 Systolic pressure, mm Hg 125·0 (119·0–135·0) 145·0 (123·0–167·0) 122·0 (118·5–129·5) 0·018 Respiratory rate >24 breaths per min 12 (29%) 8 (62%) 4 (14%) 0·0023 Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and no ICU care are from χ2 test, Fisher's exact test, or Mann-Whitney U test. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit. Open table in a new tab 27 (66%) patients had direct exposure to Huanan seafood market (figure 1B). Market exposure was similar between the patients with ICU care (nine [69%]) and those with non-ICU care (18 [64%]). The symptom onset date of the first patient identified was Dec 1, 2019. None of his family members developed fever or any respiratory symptoms. No epidemiological link was found between the first patient and later cases. The first fatal case, who had continuous exposure to the market, was admitted to hospital because of a 7-day history of fever, cough, and dyspnoea. 5 days after illness onset, his wife, a 53-year-old woman who had no known history of exposure to the market, also presented with pneumonia and was hospitalised in the isolation ward. The most common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38; table 1). More than half of patients (22 [55%] of 40) developed dyspnoea. The median duration from illness onset to dyspnoea was 8·0 days (IQR 5·0–13·0). The median time from onset of symptoms to first hospital admission was 7·0 days (4·0–8·0), to shortness of breath was 8·0 days (5·0–13·0), to ARDS was 9·0 days (8·0–14·0), to mechanical ventilation was 10·5 days (7·0–14·0), and to ICU admission was 10·5 days (8·0–17·0; figure 2). Figure 2Timeline of 2019-nCoV cases after onset of illness View Large Image Figure Viewer Download Hi-res image Download (PPT) The blood counts of patients on admission showed leucopenia (white blood cell count less than 4 × 109/L; ten [25%] of 40 patients) and lymphopenia (lymphocyte count <1·0 × 109/L; 26 [63%] patients; table 2). Prothrombin time and D-dimer level on admission were higher in ICU patients (median prothrombin time 12·2 s [IQR 11·2–13·4]; median D-dimer level 2·4 mg/L [0·6–14·4]) than non-ICU patients (median prothrombin time 10·7 s [9·8–12·1], p=0·012; median D-dimer level 0·5 mg/L [0·3–0·8], p=0·0042). Levels of aspartate aminotransferase were increased in 15 (37%) of 41 patients, including eight (62%) of 13 ICU patients and seven (25%) of 28 non-ICU patients. Hypersensitive troponin I (hs-cTnI) was increased substantially in five patients, in whom the diagnosis of virus-related cardiac injury was made. Table 2Laboratory findings of patients infected with 2019-nCoV on admission to hospital All patients (n=41) ICU care (n=13) No ICU care (n=28) p value White blood cell count, × 109/L 6·2 (4·1–10·5) 11·3 (5·8–12·1) 5·7 (3·1–7·6) 0·011 <4 10/40 (25%) 1/13 (8%) 9/27 (33%) 0·041 4–10 18/40 (45%) 5/13 (38%) 13/27 (48%) .. >10 12/40 (30%) 7/13 (54%) 5/27 (19%) .. Neutrophil count, × 109/L 5·0 (3·3–8·9) 10·6 (5·0–11·8) 4·4 (2·0–6·1) 0·00069 Lymphocyte count, × 109/L 0·8 (0·6–1·1) 0·4 (0·2–0·8) 1·0 (0·7–1·1) 0·0041 <1·0 26/41 (63%) 11/13 (85%) 15/28 (54%) 0·045 ≥1·0 15/41 (37%) 2/13 (15%) 13/28 (46%) .. Haemoglobin, g/L 126·0 (118·0–140·0) 122·0 (111·0–128·0) 130·5 (120·0–140·0) 0·20 Platelet count, × 109/L 164·5 (131·5–263·0) 196·0 (165·0–263·0) 149·0 (131·0–263·0) 0·45 <100 2/40 (5%) 1/13 (8%) 1/27 (4%) 0·45 ≥100 38/40 (95%) 12/13 (92%) 26/27 (96%) .. Prothrombin time, s 11·1 (10·1–12·4) 12·2 (11·2–13·4) 10·7 (9·8–12·1) 0·012 Activated partial thromboplastin time, s 27·0 (24·2–34·1) 26·2 (22·5–33·9) 27·7 (24·8–34·1) 0·57 D-dimer, mg/L 0·5 (0·3–1·3) 2·4 (0·6–14·4) 0·5 (0·3–0·8) 0·0042 Albumin, g/L 31·4 (28·9–36·0) 27·9 (26·3–30·9) 34·7 (30·2–36·5) 0·00066 Alanine aminotransferase, U/L 32·0 (21·0–50·0) 49·0 (29·0–115·0) 27·0 (19·5–40·0) 0·038 Aspartate aminotransferase, U/L 34·0 (26·0–48·0) 44·0 (30·0–70·0) 34·0 (24·0–40·5) 0·10 ≤40 26/41 (63%) 5/13 (38%) 21/28 (75%) 0·025 >40 15/41 (37%) 8/13 (62%) 7/28 (25%) .. Total bilirubin, mmol/L 11·7 (9·5–13·9) 14·0 (11·9–32·9) 10·8 (9·4–12·3) 0·011 Potassium, mmol/L 4·2 (3·8–4·8) 4·6 (4·0–5·0) 4·1 (3·8–4·6) 0·27 Sodium, mmol/L 139·0 (137·0–140·0) 138·0 (137·0–139·0) 139·0 (137·5–140·5) 0·26 Creatinine, μmol/L 74·2 (57·5–85·7) 79·0 (53·1–92·7) 73·3 (57·5–84·7) 0·84 ≤133 37/41 (90%) 11/13 (85%) 26/28 (93%) 0·42 >133 4/41 (10%) 2/13 (15%) 2/28 (7%) .. Creatine kinase, U/L 132·5 (62·0–219·0) 132·0 (82·0–493·0) 133·0 (61·0–189·0) 0·31 ≤185 27/40 (68%) 7/13 (54%) 20/27 (74%) 0·21 >185 13/40 (33%) 6/13 (46%) 7/27 (26%) .. Lactate dehydrogenase, U/L 286·0 (242·0–408·0) 400·0 (323·0–578·0) 281·0 (233·0–357·0) 0·0044 ≤245 11/40 (28%) 1/13 (8%) 10/27 (37%) 0·036 >245 29/40 (73%) 12/13 (92%) 17/27 (63%) .. Hypersensitive troponin I, pg/mL 3·4 (1·1–9·1) 3·3 (3·0–163·0) 3·5 (0·7–5·4) 0·075 >28 (99th percentile) 5/41 (12%) 4/13 (31%) 1/28 (4%) 0·017 Procalcitonin, ng/mL 0·1 (0·1–0·1) 0·1 (0·1–0·4) 0·1 (0·1–0·1) 0·031 <0·1 27/39 (69%) 6/12 (50%) 21/27 (78%) 0·029 ≥0·1 to <0·25 7/39 (18%) 3/12 (25%) 4/27 (15%) .. ≥0·25 to <0·5 2/39 (5%) 0/12 2/27 (7%) .. ≥0·5 3/39 (8%) 3/12 (25%) * 0/27 .. Bilateral involvement of chest radiographs 40/41 (98%) 13/13 (100%) 27/28 (96%) 0·68 Cycle threshold of respiratory tract 32·2 (31·0–34·5) 31·1 (30·0–33·5) 32·2 (31·1–34·7) 0·39 Data are median (IQR) or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and no ICU care are from χ2, Fisher's exact test, or Mann-Whitney U test. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit. * Complicated typical secondary infection during the first hospitalisation. Open table in a new tab Most patients had normal serum levels of procalcitonin on admission (procalcitonin <0·1 ng/mL; 27 [69%] patients; table 2). Four ICU patients developed secondary infections. Three of the four patients with secondary infection had procalcitonin greater than 0·5 ng/mL (0·69 ng/mL, 1·46 ng/mL, and 6·48 ng/mL). On admission, abnormalities in chest CT images were detected among all patients. Of the 41 patients, 40 (98%) had bilateral involvement (table 2). The typical findings of chest CT images of ICU patients on admission were bilateral multiple lobular and subsegmental areas of consolidation (figure 3A). The representative chest CT findings of non-ICU patients showed bilateral ground-glass opacity and subsegmental areas of consolidation (figure 3B). Later chest CT images showed bilateral ground-glass opacity, whereas the consolidation had been resolved (figure 3C). Figure 3Chest CT images Show full caption View Large Image Figure Viewer Download Hi-res image Download (PPT) Initial plasma IL1B, IL1RA, IL7, IL8, IL9, IL10, basic FGF, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNFα, and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults (appendix pp 6–7). Plasma levels of IL5, IL12p70, IL15, Eotaxin, and RANTES were similar between healthy adults and patients infected with 2019-nCoV. Further comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFα were higher in ICU patients than non-ICU patients. All patients had pneumonia. Common complications included ARDS (12 [29%] of 41 patients), followed by RNAaemia (six [15%] patients), acute cardiac injury (five [12%] patients), and secondary infection (four [10%] patients; table 3). Invasive mechanical ventilation was required in four (10%) patients, with two of them (5%) had refractory hypoxaemia and received extracorporeal membrane oxygenation as salvage therapy. All patients were administered with empirical antibiotic treatment, and 38 (93%) patients received antiviral therapy (oseltamivir). Additionally, nine (22%) patients were given systematic corticosteroids. A comparison of clinical features between patients who received and did not receive systematic corticosteroids is in the appendix (pp 1–5). Table 3Treatments and outcomes of patients infected with 2019-nCoV All patients (n=41) ICU care (n=13) No ICU care (n=28) p value Duration from illness onset to first admission 7·0 (4·0–8·0) 7·0 (4·0–8·0) 7·0 (4·0–8·5) 0·87 Complications Acute respiratory distress syndrome 12 (29%) 11 (85%) 1 (4%) <0·0001 RNAaemia 6 (15%) 2 (15%) 4 (14%) 0·93 Cycle threshold of RNAaemia 35·1 (34·7–35·1) 35·1 (35·1–35·1) 34·8 (34·1–35·4) 0·35 Acute cardiac injury * 5 (12%) 4 (31%) 1 (4%) 0·017 Acute kidney injury 3 (7%) 3 (23%) 0 0·027 Secondary infection 4 (10%) 4 (31%) 0 0·0014 Shock 3 (7%) 3 (23%) 0 0·027 Treatment Antiviral therapy 38 (93%) 12 (92%) 26 (93%) 0·46 Antibiotic therapy 41 (100%) 13 (100%) 28 (100%) NA Use of corticosteroid 9 (22%) 6 (46%) 3 (11%) 0·013 Continuous renal replacement therapy 3 (7%) 3 (23%) 0 0·027 Oxygen support .. .. .. <0·0001 Nasal cannula 27 (66%) 1 (8%) 26 (93%) .. Non-invasive ventilation or high-flow nasal cannula 10 (24%) 8 (62%) 2 (7%) .. Invasive mechanical ventilation 2 (5%) 2 (15%) 0 .. Invasive mechanical ventilation and ECMO 2 (5%) 2 (15%) 0 .. Prognosis .. .. .. 0·014 Hospitalisation 7 (17%) 1 (8%) 6 (21%) .. Discharge 28 (68%) 7 (54%) 21 (75%) .. Death 6 (15%) 5 (38%) 1 (4%) .. Data are median (IQR) or n (%). p values are comparing ICU care and no ICU care. 2019-nCoV=2019 novel coronavirus. ICU=intensive care unit. NA=not applicable. ECMO=extracorporeal membrane oxygenation. * Defined as blood levels of hypersensitive troponin I above the 99th percentile upper reference limit (>28 pg/mL) or new abnormalities shown on electrocardiography and echocardiography. Open table in a new tab As of Jan 22, 2020, 28 (68%) of 41 patients have been discharged and six (15%) patients have died. Fitness for discharge was based on abatement of fever for at least 10 days, with improvement of chest radiographic evidence and viral clearance in respiratory samples from upper respiratory tract.

Procedures We obtained epidemiological, demographic, clinical, laboratory, management, and outcome data from patients' medical records. Clinical outcomes were followed up to Jan 25, 2020. If data were missing from the records or clarification was needed, we obtained data by direct communication with attending doctors and other health-care providers. All data were checked by two physicians (XD and YQ). Laboratory confirmation of 2019-nCoV was done in four different institutions: the Chinese CDC, the Chinese Academy of Medical Science, Academy of Military Medical Sciences, and Wuhan Institute of Virology, Chinese Academy of Sciences. Throat-swab specimens from the upper respiratory tract that were obtained from all patients at admission were maintained in viral-transport medium. 2019-nCoV was confirmed by real-time RT-PCR using the same protocol described previously. 3 RT-PCR detection reagents were provided by the four institutions. Other respiratory viruses including influenza A virus (H1N1, H3N2, H7N9), influenza B virus, respiratory syncytial virus, parainfluenza virus, adenovirus, SARS coronavirus (SARS-CoV), and MERS coronavirus (MERS-CoV) were also examined with real-time RT-PCR Sputum or endotracheal aspirates were obtained at admission for identification of possible causative bacteria or fungi. Additionally, all patients were given chest x-rays or chest CT. Outcomes We describe epidemiological data (ie, short-term [occasional visits] and long-term [worked at or lived near] exposure to Huanan seafood market); demographics; signs and symptoms on admission; comorbidity; laboratory results; co-infection with other respiratory pathogens; chest radiography and CT findings; treatment received for 2019-nCoV; and clinical outcomes. Statistical analysis We present continuous measurements as mean (SD) if they are normally distributed or median (IQR) if they are not, and categorical variables as count (%). For laboratory results, we also assessed whether the measurements were outside the normal range. We used SPSS (version 26.0) for all analyses. Role of the funding source The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Research in context Evidence before this study We searched PubMed on Jan 25, 2020, for articles that describe the epidemiological and clinical characteristics of the 2019 novel coronavirus (2019-nCoV) in Wuhan, China, using the search terms “novel coronavirus” and “pneumonia” with no language or time restrictions. Previously published research discussed the epidemiological and clinical characteristics of severe acute respiratory syndrome coronavirus or Middle East respiratory syndrome coronavirus, and primary study for the evolution of the novel coronavirus from Wuhan. The only report of clinical features of patients infected with 2019-nCoV was published on Jan 24, 2020, with 41 cases included. Added value of this study We have obtained data on 99 patients in Wuhan, China, to further explore the epidemiology and clinical features of 2019-nCoV. This study is, to our knowledge, the largest case series to date of 2019-nCoV infections, with 99 patients who were transferred to Jinyintan Hospital from other hospitals all over Wuhan, and provides further information on the demographic, clinical, epidemiological, and laboratory features of patients. It presents the latest status of 2019-nCoV infection in China and is an extended investigation of the previous report, with 58 extra cases and more details on combined bacterial and fungal infections. In all patients admitted with medical comorbidities of 2019-nCoV, a wide range of clinical manifestations can be seen and are associated with substantial outcomes. Implications of all the available evidence The 2019-nCoV infection was of clustering onset, is more likely to affect older men with comorbidities, and could result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. Early identification and timely treatment of critical cases of 2019-nCoV are important. Effective life support and active treatment of complications should be provided to effectively reduce the severity of patients' conditions and prevent the spread of this new coronavirus in China and worldwide.

Methods Study design and participants For this retrospective, single-centre study, we recruited patients from Jan 1 to Jan 20, 2020, at Jinyintan Hospital in Wuhan, China. Jinyintan Hospital is a hospital for adults (ie, aged ≥14 years) specialising in infectious diseases. According to the arrangements put in place by the Chinese Government, adult patients were admitted centrally to the hospital from the whole of Wuhan without selectivity. All patients at Jinyintan Hospital who were diagnosed as having 2019-nCoV pneumonia according to WHO interim guidance were enrolled in this study. 4 All the data of included cases have been shared with WHO. The study was approved by Jinyintan Hospital Ethics Committee and written informed consent was obtained from patients involved before enrolment when data were collected retrospectively.

Introduction Since Dec 8, 2019, several cases of pneumonia of unknown aetiology have been reported in Wuhan, Hubei province, China. 1 , 2 , 3 Most patients worked at or lived around the local Huanan seafood wholesale market, where live animals were also on sale. In the early stages of this pneumonia, severe acute respiratory infection symptoms occurred, with some patients rapidly developing acute respiratory distress syndrome (ARDS), acute respiratory failure, and other serious complications. On Jan 7, a novel coronavirus was identified by the Chinese Center for Disease Control and Prevention (CDC) from the throat swab sample of a patient, and was subsequently named 2019-nCoV by WHO. 4 Coronaviruses can cause multiple system infections in various animals and mainly respiratory tract infections in humans, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 5 , 6 , 7 Most patients have mild symptoms and good prognosis. So far, a few patients with 2019-nCoV have developed severe pneumonia, pulmonary oedema, ARDS, or multiple organ failure and have died. All costs of 2019-nCoV treatment are covered by medical insurance in China. At present, information regarding the epidemiology and clinical features of pneumonia caused by 2019-nCoV is scarce. 1 , 2 , 3 In this study, we did a comprehensive exploration of the epidemiology and clinical features of 99 patients with confirmed 2019-nCoV pneumonia admitted to Jinyintan Hospital, Wuhan, which admitted the first patients with 2019-nCoV to be reported on.

Summary Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020. Findings Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market. The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical manifestations of fever (82 [83%] patients), cough (81 [82%] patients), shortness of breath (31 [31%] patients), muscle ache (11 [11%] patients), confusion (nine [9%] patients), headache (eight [8%] patients), sore throat (five [5%] patients), rhinorrhoea (four [4%] patients), chest pain (two [2%] patients), diarrhoea (two [2%] patients), and nausea and vomiting (one [1%] patient). According to imaging examination, 74 (75%) patients showed bilateral pneumonia, 14 (14%) patients showed multiple mottling and ground-glass opacity, and one (1%) patient had pneumothorax. 17 (17%) patients developed acute respiratory distress syndrome and, among them, 11 (11%) patients worsened in a short period of time and died of multiple organ failure. Interpretation The 2019-nCoV infection was of clustering onset, is more likely to affect older males with comorbidities, and can result in severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In general, characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia. Further investigation is needed to explore the applicability of the MuLBSTA score in predicting the risk of mortality in 2019-nCoV infection. Funding National Key R&D Program of China.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Prof Nanshan Chen, MD † Prof Min Zhou, MD † Xuan Dong, PhD † Prof Jieming Qu, MD † Fengyun Gong, MD Yang Han, PhD Prof Yang Qiu, PhD Jingli Wang, MD Ying Liu, MD Yuan Wei, MD Jia'an Xia, MD Ting Yu, MD Prof Xinxin Zhang, MD Prof Li Zhang, MD Show less Show footnotes Published:January 30, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30211-7

includes 8 new outcomes (5 deaths, 3 discharges). 99 case = 41 in first Lancet report + 58 subsequent cases. Adds to prior outcomes (6 dead, 28 discharged). CFR for first 41 likely in 20-25% range. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext#tbl1

Feb 2 Jump in PCR confirmed cases to 38,763 New US Cases Santa Clara Boston Santa Clara #2 San Benito Cluster Philippine fatality Lancet paper on 99 cases (original 41 plus 58) 8 new outcome (5 fatal) WHO CFR of 2.2% (not real) Re-run of fake 4 % CFR for SARS (and existing reports describing the rising CFR) Actual CFR for first 41 Wuhan cases (in 20-25% range) http://recombinomics.co/thedrnimanshow/2020/02/020220.mp3

SAN BENITO COUNTY PUBLIC HEALTH SERVICES 351 Tres Pinos Road, Suite A-202 Hollister CA 95023 831-637-5367 ENVIRONMENTAL HEALTH 351 Tres Pinos Road, Suite C-1 Hollister CA 95023 831-636-4035 MEDICAL THERAPY UNIT 761 South Street Hollister CA 95023 831-637-1989 HEALTH EDUCATION PROGRAMS 351 Tres Pinos Road, Suite A-202 Hollister CA 95023 831-637-5367 HEALTH & HUMAN SERVICES AGENCY PUBLIC HEALTH SERVICES Healthy People in Healthy Communities MARTIN FENSTERSHEIB, MD, MPH INTERIM HEALTH OFFICER TRACEY BELTON AGENCY DIRECTOR HEALTH ALERT Two Cases of 2019 Novel Coronavirus (2019-nCoV) Confirmed in San Benito County FOR IMMEDIATE RELEASE Contact: February 2, 2020 Sam Perez, MPH, Public Information Officer Tel: 831-637-5367 _____________________________________________________________________________ San Benito County, CA –Two cases of 2019-Novel Coronavirus (2019-nCoV) have been confirmed in San Benito County. The confirmed cases are related; husband and wife, and both are 57 years of age. The husband recently traveled from Wuhan, China the wife did not. Therefore, there has been person-to-person transmission. Both patients have not left their home since returning from China. San Benito County Public Health Services provided guidance for home isolation and is closely monitoring their medical condition. Currently, both patients are not hospitalized. San Benito County Public Health Services is in consultation with the Centers for Disease Control and Prevention (CDC) and the California Department of Public Health (CDPH). San Benito County Public Health Services is following all recommended guidelines. Some key points include:  If you have not been to China, or been in close contact with someone who has been to China and is sick, your risk is very low.  CDC guidance indicates that people who have casual contact with a case (in the same grocery store or movie theater) are at minimal risk of developing infection.  If you have recently been to China and feel sick, please  Stay home and avoid contact with others.  Contact your doctor’s office or emergency room and tell them about your recent travels and symptoms.  Cover your mouth and nose with a tissue or your sleeve (not your hands) when coughing or sneezing. “We continue to monitor the situation closely to protect the health of San Benito County residents and limit the spread of this virus,” said Dr. Marty Fenstersheib, San Benito County Health Officer. “We are working closely with Bay Area health officials, local health care providers and community partners.” Health Alert Two cases of 2019 Novel Coronavirus (2019-nCoV) Confirmed in San Benito County “While the virus is considered a serious public health threat, based on current information, the risk to the general public in California and locally in San Benito County continues to be low at this time,” stated Dr. Fenstersheib. Symptoms of 2019-nCoV Typically, human coronaviruses cause mild-to-moderate respiratory illness. Symptoms are very similar to the flu, including fever, cough, congestion, and/or shortness of breath. Older adults and people with underlying health conditions may be at increased risk for severe disease. Tips to Protect Yourself and Others No additional precautions are recommended at this time beyond the simple daily precautions that everyone should always take, such as: 1. Washing hands with liquid soap and water, and rubbing for at least 20 seconds; 2. Covering your mouth and nose with a tissue or your sleeve (not your hands) when coughing or sneezing; and 3. Staying home if you are sick. Since flu activity will continue to remain high during this flu season, and symptoms of coronavirus are similar to the flu, SBC PHS also recommends getting a flu shot to protect yourself and others from the flu. This is an emerging, rapidly evolving situation, and the information contained in this health alert may change quickly. SBC PHS will provide updated information as it becomes available. More information is available at https://.cdc.gov/coronavirus/2019-ncov/index.html or by calling 800-CDC-INFO | (800-232-4636) | TTY: (888) 232-6348. You can also contact San Benito County Public Health Services at (831) 637-5367 or go to the website at http://hhsa.cosb.us/publichealth/. https://bnonews.com/wp-content/uploads/2020/02/222020Case.pdf

nCoV confirmed in 57M San Benito ex-Wuhan who passed it on to wife, 57F, in San Benito County

County of Santa Clara Public Health Department Reports Second Case of Novel (new) Coronavirus Highlights · The second case of novel (new) coronavirus in Santa Clara County. · The second case is not related to the first case. · There is no immediate threat to the general public. The County of Santa Clara Public Health Department received confirmation this morning from the Centers for Disease Control and Prevention (CDC) of a second case of the novel (new) coronavirus. This second case is in an adult female. This Santa Clara County case is not related to the first case but they both had recently traveled to Wuhan, China. She is a visitor to this county and arrived January 23 to visit family. She has stayed home since she arrived, except for two times to seek outpatient medical care. She has been regularly monitored and was never sick enough to be hospitalized Family members have also been isolated, which means that they do not leave the house, even to buy groceries. The Public Health Department provides food and other necessary items. Since the investigation has just begun, further information about the individual will not be released at this time. “I understand that people are concerned, but based on what we know today, the risk to general public remains low,” said Dr. Sara Cody, Health Officer, Santa Clara County. “A second case is not unexpected. With our large population and the amount of travel to China for both personal and business reasons, we will likely see more cases, including close contacts to our cases.” Because much is unknow about how the novel coronavirus spreads, current knowledge is largely based on what is known about similar coronavirus. Santa Clara County residents, students, workers, and visitors should continue to engage in their regular activities and practice good health hygiene since this is the height of flu season. Healthy people should not be excluded from activities based on their race, country of origin, or recent travel. Anyone with respiratory symptoms, such as a cough, sore throat, or fever, should stay home, practice proper cough etiquette and hand hygiene, and limit their contact with other people. County of Santa Clara Public Health Department is working closely with the CDC, the California Public Health Department and other partners as the new coronavirus situation continues to change. Information will be updated as soon as possible on our website: http://sccphd.org/coronavirus Last updated: 2/2/2020 3:37 PM https://www.sccgov.org/sites/phd/news/Pages/second-novel-coronavirus-case-02-2020.aspx